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A B S T R A C T
Reactive oxygen and nitrogen species (ROS and RNS, e.g. H2O2, nitric oxide) confer redox regulation of essential
cellular signaling pathways such as cell diﬀerentiation, proliferation, migration and apoptosis. At higher
concentrations, ROS and RNS lead to oxidative stress and oxidative damage of biomolecules (e.g. via formation
of peroxynitrite, fenton chemistry). Peripheral artery disease (PAD) is characterized by severe ischemic
conditions in the periphery leading to intermittent claudication and critical limb ischemia (end stage). It is
well known that redox biology and oxidative stress play an important role in this setting. We here discuss the
major pathways of oxidative stress and redox signaling underlying the disease progression with special emphasis
on the contribution of inﬂammatory processes. We also highlight therapeutic strategies comprising pharmaco-
logical (e.g. statins, angiotensin-converting enzyme inhibitors, phosphodiesterase inhibition) and non-pharma-
cological (e.g. exercise) interventions. Both of these strategies induce potent indirect antioxidant and anti-
inﬂammatory mechanisms that may contribute to an improvement of PAD associated complications and disease
progression by removing excess formation of ROS and RNS (e.g. by ameliorating primary complications such as
hyperlipidemia and hypertension) as well as the normalization of the inﬂammatory phenotype suppressing the
progression of atherosclerosis.
1. Introduction
1.1. Redox regulation versus oxidative stress
There is ample evidence that many diseases and drug-induced
complications are associated with or even based on increased levels
of reactive oxygen and nitrogen species (ROS and RNS), so-called
oxidative stress [1,2]. In contrast, redox regulation is the process in
which ROS and RNS act as signaling molecules by reversible redox
modiﬁcations in enzymes that aﬀect cellular processes (e.g. S-nitrosa-
tion of caspase-3 to control apoptosis [3], NFκB activation via thiol
oxidation mediated IκB degradation [4]) [5,6]. Chronic oxidative stress
conditions will lead to the accumulation of posttranslational oxidative
modiﬁcations in biomolecules (e.g. protein carbonylation or aldehyde/
ketone adducts, nitration and sulfoxidation, DNA lesions such as 8-oxo-
dG) and interference with physiological redox signaling (e.g. impaired
H2O2 signaling in essential cellular processes) [7,8]. Many cardiovas-
cular, neurodegenerative, and inﬂammatory diseases as well as cancer
are associated or even triggered by oxidative stress [9–13] and there is
at least strong clinical evidence that the severity of these diseases in
most cases correlates with the levels of established redox biomarkers
(reviewed in a critical position paper [14]), although the causal role of
oxidative stress in the clinical setting remains under heavy debate (for
contra see [15], for pro see [1,16]).
Despite the above mentioned oxidative stress concept in disease
progression most large scale clinical studies on the eﬃcacy of orally-
administrated antioxidants (namely vitamins) in patients turned out
neutral (e.g. HOPE, HOPE-TOO; for review see [1,17,18]) or even
showed negative outcome (e.g. for vitamin E) [17,19–21]. These
disappointing results are contrasted by numerous small cohort studies
with acute (short-term) and/or high dose administration (e.g. via
infusion) of antioxidants showing positive outcome in various diseases
(reviewed in [1,17,22]). The reasons for this obvious discrepancy were
reviewed in very detail and most probably comprise that systemic
therapy with non-speciﬁc antioxidants interferes with essential physio-
logical redox signaling pathways aﬀecting cell diﬀerentiation, prolif-
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eration, migration and apoptosis, as well as life-essential stress adapta-
tion pathways (e.g. ischemic preconditioning-like pathways, Nrf2/
heme oxygenase-1 antioxidant pathway) [1,17,18].
In the subsequent chapters we will discuss the role of redox
signaling and oxidative stress in ischemia/reperfusion damage in
general (critically reviewed in [23]) and in peripheral artery disease
(PAD) in particular, also largely based on our own clinical observations
[24–27]. As early as 1977 it was proposed that autoxidation processes
(loss of endogenous antioxidants) might be involved in the pathophy-
siology of PAD in humans [28]. According to recent state-of-the art
studies and reviews, markers of oxidative damage (e.g. 4-hydroxyno-
nenal and protein carbonyls) increased with clinical stage of disease,
blood ﬂow limitation in the ischemic leg, and reduced myoﬁber cross-
sectional area and oxidative stress was therefore proposed as possible
cause of PAD in humans [29–31]. The underlying pathology of PAD
comprises ischemia reperfusion and chronic inﬂammation, both pro-
cesses that were shown in vivo and ex vivo to be redox regulated [32].
1.2. Redox regulation and oxidative stress in ischemia/reperfusion
Ischemia/reperfusion injury (IRI) is a main feature of various
cardiovascular diseases like myocardial infarction, stroke and PAD
[33,34]. IRI begins with occlusion of a vessel followed by interruption
of the blood ﬂow and temporary lack of oxygen and nutrients.
Oxidative phosphorylation is disturbed and generation of adenosine
triphosphate (ATP) reduced. Inactivity of the Na+/K+ pump results in
intracellular calcium overload causing apoptotic and necrotic cell death
(as reviewed in [35]). This initial “oxygen poor” phase is followed by
reperfusion and recovery of demanded oxygen supply to the cells.
However, this phase is accompanied by an increase in ROS formation,
which leads to opening of mitochondrial permeability pore (mPTP),
lipid peroxidation, DNA damage and triggers inﬂammatory processes
(release of cytokines and upregulation of adhesion molecules) (as
reviewed in [36,37]). At this time oxygen can be seen as a “double-
edged sword” [38].
Later on in IRI and also permanent ischemia, ROS are essential
signal molecules responsible for proliferation of smooth muscle cells
and for angiogenesis mediated by vascular endothelial growth factor
(VEGF) or hypoxia-inducible factor (HIF-1) [39]. HIF-1 plays a central
role in cellular oxygen sensing with a close crosstalk with mitochondrial
sensing of hypoxia [40]. It has been shown in cultured human
endothelial cells that a decrease of ROS by use of antioxidants (N-
acetylcysteine), pharmacological inhibition or genetic knock-down of
NADPH oxidase reduces VEGF-mediated downstream activity and
neovascularization [41,42]. Mice lacking Nox4 showed impaired
recovery of blood ﬂow and angiogenesis after femoral artery ligation
[43]. Besides ROS, also RNS like peroxynitrite are involved in IRI and
chronic ischemia. eNOS-derived nitric oxide (•NO) mediates vasorelaxa-
tion and anti-proliferative properties under physiologic conditions (as
reviewed in [22]). However, during IRI, eNOS uncoupling due to
increased oxidative stress and hypoxia leads to formation of ROS
instead of •NO by the enzyme. Reduced •NO bioavailability and
increased superoxide/peroxynitrite levels follow, which causes cell
damage and impaired vascular function (as reviewed in [22,36]). In
this case ROS stimulate further ROS production by uncoupling of eNOS.
The latter mechanism is similar to mitochondria-derived oxidative
stress. Mitochondria have been described as major sources of oxidative
stress in IRI [44]. Known from animal studies and cultured human cells,
Fig. 1. The three phases of ischemia reperfusion (I/R) damage and recovery that can be also applied to disease mechanisms of peripheral artery disease. The major redox-regulated
pathways or ROS sources are illustrated in the scheme. Major players are HIF-1α, NOX1/4, mitochondria, eNOS, XO, Grx-1 either promoting or preventing necrosis/apoptosis, oxidative
stress, inﬂammation and remodeling/angiogenesis. For detailed explanation see main text. Modiﬁed from [37]. Abbreviations: HIF-1α, hypoxia-inducible factor 1α; NOX1/4, NADPH
oxidase isoform 1 or 4; XOR, xanthine oxidoreductase; deoxy-Hb, deoxy-hemoglobin; eNOS, endothelial nitric oxide synthase; XDH, xanthine dehydrogenase; XO, xanthine oxidase;
mPTP, mitochondrial permeability transition pore; MMPs, matrix-metalloproteinases; EPC, endothelial progenitor cells; Grx-1, glutaredoxin-1; VEGF, vascular endothelial growth factor.
S. Steven et al. Redox Biology 12 (2017) 787–797
788
cytosolic ROS can trigger uncoupling of the mitochondrial respiration
chain, which in turn can be released via an opened mPTP to the cytosol
with further increase of cytosolic oxidative stress as a consequence (for
review see [36,45,46]). Among the adverse eﬀects of superoxide,
hydrogen peroxide and peroxynitrite in IRI are the increase in platelet
activity and microvascular constriction/occlusion (e.g. by oxidative
inhibition of soluble guanylyl cyclase in rat aorta [47,48], nitration/
inactivation of prostacyclin synthase in cultured endothelial cells
[22,49] and activation of cyclooxygenase via increased peroxide tone
in cultured vascular smooth muscle cells [36,50]) (as reviewed in [51]),
the two major complications in IRI in general and patients with PAD in
particular.
In fact ROS play a Janus-faced role in IRI and permanent ischemia.
On the one hand they are toxic and lead to cell death, on the other, ROS
as signaling molecules mediate important compensatory mechanisms to
recover perfusion and blood supply (Fig. 1). In the ﬁrst phase of
ischemia the loss of ATP production, calcium overload and drop in pH
leads to cell death via necrosis and apoptosis. Hypoxia activates the
transcription factor hypoxia-inducible factor-1α (HIF-1α), which to-
gether with calcium overload activates NADPH oxidases. Likewise,
NADPH oxidases and ROS in general stabilize HIF-1α as studied in
pulmonary vessels from patients with pulmonary vasculopathy [52,53].
In the ischemic phase the reduction of inorganic nitrite via xanthine
oxidoreductase (XOR) and deoxy-hemoglobin/myoglobin (deoxy-Hb/
Mb) may provide nitric oxide (•NO) to improve the perfusion to
overcome hypoxia as studied in human forearm [54–58]. Due to altered
mitochondrial metabolism reduction of inorganic nitrite may serve also
as a source of •NO in hypoxic mitochondria (as reviewed in [59]). Under
normoxic conditions also bacteria in the gastrointestinal tract [60] as
well as immune cells such as macrophages (studied in mice) [61,62]
may contribute to the bioactivation of inorganic nitrite and nitrate. •NO
contributes to the stabilization of HIF-1α [63] but, via S-nitros(yl)ation,
may also protect critical thiol-dependent enzymes from oxidative
inactivation during the reperfusion phase [59]. In the second phase,
upon reperfusion, activated NADPH oxidases and hypoxia-adapted
mitochondrial respiratory chain generate huge amounts of superoxide
and hydrogen peroxide, where NADPH oxidases and mitochondria can
stimulate ROS formation from each other, which was studied in
pulmonary artery smooth muscle cells [64], leading to conversion of
xanthine dehydrogenase (XDH) to ROS-producing xanthine oxidase
(XO) and to endothelial nitric oxide synthase (eNOS) uncoupling (as
reviewed in [65,66]). Thereby, reoxygenation leads to increased
oxidative stress and diminished •NO levels, which triggers the expres-
sion of adhesion molecules, production of chemokines, oxidative DNA
damage, lipid peroxidation, activation of matrix metallo-proteinases
(MMPs) with increased inﬂammation and cytotoxicity with mostly
detrimental eﬀects for the cell (necrosis and apoptosis). However, in the
third phase of remodeling and angiogenesis (post-reperfusion) certain
subsets of immune cells and MMPs are required to repair the tissue
damage from I/R phases. •NO stimulates recruitment of endothelial
progenitor cells (EPCs) to areas with defects, ROS/RNS activate
transcription factor that initiate remodeling and angiogenesis via
vascular endothelial growth factor (VEGF). Certain levels of ROS and
RNS are required for the regulation of pro- and anti-inﬂammatory
pathways (e.g. for the suppression of the antiangiogenic p65/NFκB/
Wnt5/sFlt pathway by S-glutathionylation but also for the activation
NFκB-dependent pathways that are needed for the activation of repair-
associated inﬂammatory pathways), e.g. as produced by HIF-1α
regulated Nox2 as studied in human umbilical vein endothelial cells
(HUVECS) [67]. The mitochondrial permeability transition pore
(mPTP) plays an essential role during ischemia/reperfusion mediated
necrosis and mostly apoptosis but, by transient, repeated opening/
closing cycles can also confer long-term antioxidant protection by
induction of antioxidant defense enzymes (the concept underlying
ischemic pre- and post-conditioning [68,69]).
The recent publication by Granger and Kvietys provides an excellent
overview on the contribution of the major ROS sources xanthine
oxidase, mitochondria, NADPH oxidases and uncoupled eNOS in
ischemia/reperfusion damage and also discusses the evidence for a
vital crosstalk between these diﬀerent ROS sources in hypoxia/reox-
ygenation [70]. As studied in mice, the recovery from ischemia/
reperfusion damage is largely redox regulated by thiol oxidation
(disulﬁde), S-glutathionylation and glutaredoxin networks [71].
2. What is peripheral artery disease? Deﬁnition and clinical
importance
PAD is deﬁned as obstructive disease of non-cardiac arterial vessels
mostly aﬀecting arteries of lower extremities [72,73]. The most
common cause of PAD is atherosclerosis.
Based on current estimations about 200 million people worldwide
suﬀer from PAD [74]. Thus PAD is one of the main manifestations of
atherosclerosis. The prevalence of PAD in the general population is
3–10% [75,76], which is increased at the age of 70 years to 15–20%
[77,78]. The cardiovascular mortality within 5 years after diagnosis of
stable PAD is 11–23% [79]. The risk of major amputation is less than
2% for patients with stable PAD, whereas the risk of major amputation
within the next 12 months is increased to almost 50% in patients with
critical limb ischemia [80]. The most likely reason for the increased
cardiovascular mortality of PAD patients is the fact that they also suﬀer
from severe atherosclerosis in other (e.g. coronary) vascular territories
[79,81]. Therefore patients with PAD are at high risk of cardiovascular
events such as myocardial infarction or stroke [82].
Accordingly, the most important risk factors for the development
and progression of PAD are similar to those for atherosclerosis in
general: smoking, diabetes, hypertension and hypercholesterolemia.
The strongest associations are observed for smoking and diabetes [80].
Moreover the location of atherosclerotic manifestation in the arterial
vessel tree diﬀers according to main risk factor proﬁle. Patients with
diabetes suﬀer more often from occlusion of the lower limb arteries
while smokers develop mostly stenotic disease of the iliac or femoral
arteries [74].
As atherosclerosis is an inﬂammatory disease it is not surprising that
markers of inﬂammation such as the acute phase proteins C reactive
protein and ﬁbrinogen or pro-inﬂammatory cytokines like interleukin-6
(IL-6) and interleukin-18 (IL-18) are associated with increasing burden
of atherosclerosis [83]. In particular patients with elevated inﬂamma-
tory markers and PAD are at high risk for cardiovascular events such as
myocardial infarction, stroke or cardiovascular death.
Clinical symptoms of PAD are deﬁned by the “Fontaine” and
“Rutherford” Classiﬁcation (Table 1). The typical clinical symptom of
stable PAD is walking pain deﬁned as “intermittent claudication”
(Rutherford category 1, 2 or 3, Fontaine category II). The most severe
clinical manifestation of PAD is critical limb ischemia characterized by
Table 1.
Clinical characterization of peripheral artery disease according to the Fontaine and
Rutherford classiﬁcation. Modiﬁed from [80,84].
Fontaine Rutherford
Category Clinical symptoms Category Clinical symptoms
I Asymptomatic 0 Asymptomatic
IIa Pain-free walking
distance> 200 m
1 Mild symptoms of
intermittent claudication
IIb Pain-free walking
distance< 200 m
2 Moderate symptoms of
intermittent claudication
3 Severe symptoms of
intermittent claudication
III Pain at rest 4 Pain at rest
IV Ischemic ulcer or gangrene 5 Lesions with minor tissue
loss
6 Ischemic ulcer or gangrene
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rest pain or tissue loss (Rutherford category 4, 5 or 6, Fontaine III or IV)
[84]. In particular, patients with diabetes develop PAD with peripheral
ulcers or gangrene.
The easiest way to detect PAD independently from clinical symp-
toms is to measure ankle pressure using a blood pressure cuﬀ and a
Doppler probe. Ankle-brachial index (ABI) is calculated as relation
between systolic ankle and arm pressure [85,86]. Usually an ankle-
brachial index of 0.9 or less is deﬁned as PAD. However, PAD is often
overlooked because many patients have no clinical symptoms although
thy have a low ankle brachial index [77]. Nevertheless, asymptomatic
patients are at increased risk for cardiovascular events, too. Therefore,
screening for PAD by alternative methods is also important.
Although patients with PAD are at high cardiovascular risk, the
awareness is very low. In fact patients with PAD are often undertreated
in regard to consequent risk factor control compared to patients with
manifestations of atherosclerosis in other arterial territories such as
coronary artery disease [82].
3. Peripheral artery disease, redox signaling, oxidative stress
3.1. Evidence from animal models
In the past decades PAD has been investigated in several animal
models. Besides thrombo-embolic models, acute ligation and excision
models are mostly used for investigation of PAD in mice or rats. The
severity of experimental hind limb ischemia (HLI) depends on the
location and length of arterial occlusion. For example ligation of the
femoral artery (FA) alone results only in mild ischemia, since blood
ﬂow persists via collateral vessels. On the other hand, ligation and
excision of the complete FA and its side branches results in severe
ischemia with necrosis of the toe. Inhomogeneity of animal models and
surgical procedures limit the reliability and translation of preclinical
results in human PAD [87], although a recent report shows that the
used animal model of critical limb ischemia (by unilateral femoral and
iliac ligatures) shares key features with the human pathology including
increased muscular ROS formation [88]. Importantly in this latter study
ROS formation was measured by the gold standard technique, electron
paramagnetic resonance spectroscopy and also correlated with dihy-
droethidium staining and expression levels of antioxidant enzymes.
It is well established that smoking and diabetes mellitus, main risk
factors for PAD, promote oxidative stress and reduce •NO bioactivity,
which enhances inﬂammatory pathways (studied in humans and
HUVECs) [89,90]. In PAD, neovascularization constitutes an important
adaptive mechanism against ischemia, in which vascular endothelial
growth factor (VEGF) plays a predominant role (as reviewed in [91]).
The function of VEGF in angiogenesis largely depends on endothelium-
derived •NO, which also has been identiﬁed as a mediator of endothelial
cell migration and mobilization of endothelial progenitor cells (EPC)
from the bone marrow of mice [89,92]. Reduced bioavailability of •NO
by direct ROS-mediated break-down or oxidative uncoupling of eNOS
disturbs this pathway. Nevertheless, it cannot be generalized that ROS
formation leads to cellular toxicity and impairs angiogenesis, because
low levels of hydrogen peroxide and superoxide can serve as or are even
essential (e.g. Nox2, Nox4) as intracellular messengers and can promote
angiogenesis and reduce tissue injury. This is also supported by an
elegant study in transgenic mice overexpressing glutaredoxin-1 (Grx-1)
[93]. In these mice oxidatively induced S-glutathionylation, the essen-
tial stimulus of angiogenesis/revascularization and recovery from hind
limb ischemia, is removed continuously. In Grx-1 transgenic mice the
suppression of the p65/NFκB/Wnt5/sFlt pathway is not suppressed
suﬃciently by S-glutathionylation of p65 leading to increased sFlt
expression and reduced angiogenesis via VEGF. Likewise, increased S-
glutathionylation in Grx-1 knockout mice stabilizes HIF-1α and pro-
motes angiogenesis [94].
In support of this, Bir et. al. showed by an animal model of
compromised glutathione synthesis and reduced antioxidant capacity
(Gclm+/- mutant mice) that partly preserved glutathione synthesis,
with slightly increased oxidative stress leads to improved blood ﬂow
and angiogenesis, which was accompanied by increased VEGF levels
[95]. Higher ROS levels, however, induced by complete loss of
glutathione synthesis showed no beneﬁcial eﬀects (Gclm-/- mutant
mice) [95]. Furthermore, it has been shown that genetic deletion of
NADPH oxidase isoform 2 (Nox2), a main source of ROS in the vascular
wall, reduces ﬂow recovery and capillary density in hind limb ischemia
of Nox2 knock-out mice [96,97]. Also Nox4-derived H2O2 was shown to
be necessary for angiogenesis in mice. Deﬁciency in Nox4 led to
reduced eNOS expression, •NO production and heme oxygenase-1
(HO-1) expression, accompanied by apoptosis and inﬂammatory acti-
vation [43]. However, conditions of increased oxidative stress, as
evident in diabetes, genetic deletion of antioxidant proteins or smoking,
are deleterious for neovascularization after hind limb ischemia. Accord-
ingly Nox2 knock-out mice exposed to cigarette smoke were protected
against the detrimental eﬀects of hind limb ischemia. The latter was
accompanied by improved VEGF/•NO signaling and preserved eNOS
expression in ischemic tissue [98]. Diabetes in mice leads to reduced
eNOS expression and EPC migration in response to VEGF stimulation,
and furthermore to increased 3-nitrotyrosine levels [99]. Similar
ﬁndings were made in copper-zinc superoxide dismutase-deﬁcient mice
[100]. Likewise, mesenchymal stem cells transplanted from diabetic
db/db mice were less potent to prevent the hind limb ischemia-
dependent damage than those cells from wild type animals, but their
protective potential was improved by prior Nox4 siRNA or N-acetylcho-
line treatment [101]. In ischemic hind limbs of eNOS knock-out mice
and more severe in placental growth factor (PlGF)/eNOS double knock-
out mice, capillary density was reduced accompanied by increased
macrophage inﬁltration, iNOS expression and 3-nitrotyrosine positive
proteins [102]. As studied in mice, the loss of eNOS activity during IRI
in general and HLI in particular is eventually compensated by increased
biosynthesis of •NO from inorganic sources such as nitrate and nitrite
(by bacterial systems or xanthine oxidoreductase and deoxy-Hb), which
are obviously even more eﬃcient in ischemic tissues [57,103].
Besides cytosolic ROS formation also other ROS sources are
involved in the pathogenesis of PAD. Knock-out of p66SchA, a redox
enzyme localized in the mitochondria that generates mitochondrial
ROS as signaling molecules for apoptosis, led to faster regeneration of
muscle ﬁbers and lower oxidative stress during ischemia compared to
control animals. The importance of mitochondrial ROS formation goes
in line with recent ﬁndings of Ryan et al. who demonstrated that
mitochondria-targeted overexpression of the antioxidant enzyme cata-
lase in mice prevents high fat diet-induced ischemic limb necrosis,
myopathy and mitochondrial dysfunction, but did not alter hind limb
blood ﬂow [104]. Another study revealed mitochondrial dysfunction
(impaired respiration at complexes I, III and IV) and oxidative stress as
revealed by increased protein carbonyl and 4-hydroxynonenal content
as well as impaired activity of manganese superoxide dismutase (SOD2)
in mice with hindlimb ischemia by ligation/division of the common
femoral and iliac arteries [105]. In a model of hind limb ischemia in
diabetic ob/ob mice it was shown that unacetylated ghrelin rescues
miR-126 expression that controls sirtuin-1 and manganese superoxide
dismutase (SOD2), all of which improved the oxidative stress levels in
these animals and recovery from hind limb ischemia [106]. This also
emphasizes the potential clinical impact of targeting redox signaling
and oxidative stress in avoiding limb loss in PAD and diabetic leg
patients.
3.2. Evidence from clinical studies
Patients with PAD are limited by walking distance and can often not
participate in daily activities. Therefore, patients with PAD are at
increased risk for social isolation and depression. Reduced physical
activity is followed by higher risk for obesity, arterial hypertension,
dyslipidemia and diabetes which are all also risk factors for endothelial
S. Steven et al. Redox Biology 12 (2017) 787–797
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dysfunction and atherosclerosis (Fig. 2) [107,108]. Because of limited
blood ﬂow, nourishment of muscle cells is reduced and muscle
metabolism is impaired. In particular in the clinical stage of inter-
mittent claudication the alternation between repeated ischemia and
reperfusion triggers inﬂammation and oxidative stress
[26,27,109–111]. The risk of PAD was signiﬁcantly increased in
individuals with higher oxidized phospholipids [110] and lipid perox-
idation products such as malondialdehyde and oxidized low-density
lipoproteins (LDL) [112], which are established biomarkers of oxidative
stress. This observation was further supported by increased levels of
autoantibodies against oxidized LDL in patients with early-onset of
peripheral artery disease [113]. Serum levels of S-glutathionylated
proteins are a sensitive risk-marker for atherosclerosis in patient
collectives of PAD and negatively correlated with the ankle-brachial
index [114]. Among the reported markers of PAD there are several
associated with oxidative stress and inﬂammation [31].
We observed these eﬀects under clinical conditions in patients with
PAD. In the MonoxGo project patients with intermittent claudication,
critical limb ischemia and healthy controls were compared in regard to
the relation of pro-inﬂammatory mononuclear cells with markers of
oxidative stress. We found an increased number of pro-inﬂammatory
monocytes in patients with intermittent claudication [27]. In contrast,
patients with critical limb ischemia showed a reduced expression of
pro-inﬂammatory cells. Possibly, an adequate regulation of inﬂamma-
tory cells in this advanced stage of the disease is altered due to the
chronic ischemic milieu. This goes in line with the ﬁnding, that cells
from patients with critical limb ischemia showed signiﬁcant higher
production of reactive oxygen and nitrogen species (RONS) measured
Endothelial 
dysfuncon ↑
Ischemia
Reperfusion 
Inﬂammaon ↑
Free-radicals ↑
Altered muscle 
metabolism
Walking distance ↓
Quality of life ↓
Oxygen delivery ↓
Obesity ↑
Arterial hypertension ↑
Dyslipidemia↑
Diabetes risk ↑
Muscle-ﬁber 
atrophy ↑
Peripheral 
artery disease 
(PAD)
Aerobic capacity↓ 
Muscle strength ↓
Fig. 2. Pathophysiological disabilities associated with peripheral artery disease. Modiﬁed from [107,108].
Fig. 3. Correlation of the marker of inﬂammation soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) with oxidative stress and walking distance in PAD patients with
intermittent claudication. We found an inverse correlation for sTREM-1 with the absolute (r=−0.479; p=0.002) (A), a direct correlation with whole blood oxidative burst after phorbol
ester stimulation (r=0.565; p=0.0001) (B) and the general markers of inﬂammation ﬁbrinogen (r=0.532; p=0.0004) (C) and CRP (r =0.263; p=0.1002) (D). Number of patients was
n=40. Adapted from [25]. With permission of Springer-Verlag Berlin Heidelberg. Copyright © 2015.
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by L-012 (luminol analogue) chemiluminescence at baseline and after
stimulation by phorbol ester [26]. In patients with intermittent
claudication, we observed a highly signiﬁcant inverse correlation
between the marker of inﬂammation triggering receptor expressed on
myeloid cells-1 (TREM-1) with the absolute as well as the pain-free
walking distance, a positive correlation with whole blood oxidative
burst (measured by L-012 chemiluminescence) and ﬁbrinogen, repre-
senting a general marker of inﬂammation, whereas for C-reactive
protein (CRP) only a trend for a relationship was observed (Fig. 3) [25].
One of the most important mechanisms to prevent or resolve muscle
ischemia is the stimulation of collateral vessel growth. Collateral
growth underlies multiple pathophysiological mechanisms. To under-
stand these causal relations is the key to develop new therapeutic
strategies. In this regard, shear stress seems to be of importance.
Arteries react to shear stress with diameter growth and endothelial
remodeling [115], in addition to an up-regulation of adhesion mole-
cules on the endothelial surface.
Under stable conditions such as in patients with intermittent
claudication, blood ﬂow is increased in the aﬀected limb and may
contribute to the resolution of tissue damage. In critical limb ischemia
these compensatory responses to ischemia are ineﬀective [31,116]. In
consequence, ongoing insuﬃcient tissue perfusion leads to chronic
inﬂammation and oxidative stress. Under this pathophysiological
hypothesis, we evaluated in particular patients with critical limb
ischemia with regard to mononuclear cells potentially involved in
angiogenesis [117]. For these patients we found a strong association of
inﬂammatory markers (C-reactive protein [CRP], ﬁbrinogen) with a
reduced proportion of pro-angiogenic Tie-2 expressing monocytes
(TEM) or endothelial progenitor cells (EPC). Accordingly, we hypothe-
size that a severe chronic inﬂammation can have negative eﬀects on
potential pro-angiogenic cells and thus inhibit repair mechanism in
ischemic tissue. In conclusion, it seems very important to react in
earlier stages of the disease when protective mechanism can still be
stimulated.
3.3. Therapy of peripheral artery occlusive disease
Patients with PAD are at increased risk for cardiovascular events.
Therefore, therapeutic strategies for risk reduction are crucial in PAD
patients [118]. In particular statins, ACE-inhibitors are highly eﬀective
to improve cardiovascular prognosis in PAD patients, most probably by
reducing primary PAD-associated complications such as hypertension,
inﬂammation and hyperlipidemia, all of which confers antioxidant,
anti-inﬂammatory and anti-atherosclerotic eﬀects [119,120]. In sup-
port of the importance of •NO in the therapeutic concepts, and in line
with the mentioned beneﬁts of •NO from inorganic nitrite and nitrate
sources in ischemia/reperfusion (see Section 1.2 and Fig. 1), also
inorganic nitrate therapy increased the pain-free walking distance of
Fig. 4. Positive eﬀects of exercise training on peripheral perfusion in patients with intermittent claudication. (A) Summary of potential beneﬁcial eﬀects of exercise training on PAD.
Modiﬁed from [108,110,116]. With permission of Massachusetts Medical Society. Copyright © 2002. (B, C) Original data on decreased oxidative burst in phorbol ester stimulated whole
blood (measured by L-012 ECL) and expression of the pro-inﬂammatory molecule sTREM-1 on monocytes of PAD patients with intermittent claudication after exercise. Number of
patients was n=40.Adapted from [25]. With permission of Springer-Verlag Berlin Heidelberg. Copyright © 2015.
S. Steven et al. Redox Biology 12 (2017) 787–797
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claudicants [121]. There are diﬀerent therapeutic strategies to treat
PAD aimed to bring back blood to ischemic tissue. One strategy is to re-
open arteries by endovascular intervention or to bypass occluded
arteries by venous or synthetic grafts [122]. After successful revascu-
larization, wound healing and pain-free walking distance are improved.
This has of course positive eﬀects on inﬂammation and oxidative stress
[123]. Nevertheless, one still has to assume future vessel restenosis or
graft occlusion after interventional therapies.
It is of current interest to develop strategies to improve collateral
vessel growth in PAD patients. A number of studies investigated gene
therapies or cell-based therapies to provoke new vessel formation, but
most of these could not satisfy the expectations [84]. Neither direct
antioxidant therapies with modern antioxidant concepts such as
NADPH oxidase inhibitors or activators of intrinsic antioxidant path-
ways such as Nrf2 activators nor direct anti-inﬂammatory therapy by
monoclonal antibodies against chemokines have been investigated so
far in human PAD. However, experimental and human observational
data suggest that antioxidant and anti-inﬂammatory strategies may be
successful in PAD patients (see preceding chapters) [124,125]. Endo-
vascular therapy improved blood ﬂow, walking distance and oxidative
stress parameters in patients with PAD [123]. Recently, it was shown
that dark chocolate improves the walking distance and •NO production
and decrease isoprostane levels in PAD patients, most likely by eﬀects
of antioxidant components of dark chocolate on NADPH oxidase
activity [126], as previously shown for the improvement of endothelial
function by ﬂow-mediated dilation measurements [127]. Likewise,
supplementation with N-acetylcysteine could be a candidate for anti-
oxidant therapy of PAD patients since this drug was shown to improve
human coronary and peripheral endothelium-dependent vasodilation
[128].
In contrast the “natural” way to improve collateralization by
exercise training seems to be more successful in particular for patients
with intermittent claudication. Exercise has multiple positive eﬀects for
the limb perfusion but also confers systemic beneﬁcial eﬀects (Fig. 4)
[107,108,116]. In general, physical activity has been shown to greatly
improve cardiovascular function, in part through improved bioavail-
ability of •NO, enhanced endogenous antioxidant defense and a low-
ering of the expression of enzymes involved in ROS production [129].
We reported decreased oxidative burst and sTREM expression in
leukocytes of PAD patients with intermittent claudication after exercise
training [25].
To evaluate the eﬀects of exercise training on systemic inﬂamma-
tion and oxidative stress we asked 40 patients with intermittent
claudication to perform a home-based exercise training program for a
mean duration of 12 months. In this setting we observed an improve-
ment of the inﬂammatory phenotypes of mononuclear cell populations,
reduction of systemic inﬂammatory markers and reduction of ROS
production [25]. These changes were associated with an improvement
of walking distance.
Previous studies consistently show better eﬀects on pain-free and
maximal walking distance if exercise training is performed under
Fig. 5. Proposed hypothesis on the role of oxidative stress, neutrophils (PMN) and
monocytes in peripheral artery disease (PAD). In PAD patients platelets are strongly
activated. Also markers of inﬂammation like triggering receptor expressed on myeloid
cells-1 (TREM-1) were largely increased in plasma of PAD patients. PMN and monocytes
are stimulated via Interaction of TREM-ligand with TREM-1, which leads to an increased
production of ROS. This will further increase endothelial ROS formation, possibly via
NADPH oxidases, which then might activate even more platelets, thus leading to a
positive feedback mechanism. The increased burden of vascular ROS will potentially also
inhibit endothelial nitric oxide (•NO) formation, which will ultimately lead to vascular
dysfunction and progression of atherosclerosis. Whether mitochondrial ROS are involved
in immune cell activation and subsequent tissue damage by inﬁltrating immune cells is
likely but remains to be demonstrated in patients with PAD. sTREM being shedded by
PMN and monocytes might further stimulate chronic inﬂammation or act as a regulatory
molecule to regulate the response of the innate immune system to the inﬂammatory
stimulus in atherosclerosis. The scheme summarizes our previous ﬁndings [26,27].
Without impairment of 
quality of life  
With impairment of 
quality of life  
Revascularization 
(angioplasty, bypass) 
Improvement of 
clinical symptoms 
No improvement of 
clinical symptoms 
Intermittent 
claudication 
Critical limb 
ischemia 
- Exercise training 
- Cilostazol 
regular 
controls 
• Smoking cessation 
• Statin therapy 
• Anti-platelet drugs 
• Blood pressure control 
(e.g. ACEi) 
• Glucose control 
PAD 
Proximal lesion  
(aortal or iliacal) 
Fig. 6. Proposed treatment regimen for patients with PAD. Modiﬁed from [80].
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standardized conditions [80]. Therefore we were interested in the
eﬀects of a supervised exercise training on angiogenic cells in compar-
ison to a home-based non-supervised exercise training [24]. In total 20
patients with intermittent claudication performed supervised exercise
training and 20 patients performed non-supervised home-based train-
ing. We found positive eﬀects in both training groups on circulating
angiogenic progenitor cells and pro-angiogenic Tie-2 expressing mono-
cytes (TEM). However, the supervised form of exercise training was
more eﬃcient than the home-based form in regard to individual
improvement of the walking distance or amelioration of inﬂammation
or VEGF [24,117].
In the case that exercise training is not possible or improvement of
walking distance is not satisfactory, some drugs can improve walking
distance too [118]. One of these drugs is cilostazol, which causes
peripheral vasodilatation and inhibits platelet aggregation. In addition
several studies showed reduction of restenosis after peripheral or
coronary interventions [130]. However, another current study did not
ﬁnd eﬀects of cilostazol on systemic markers for oxidative stress in a
small population of PAD patients [131].
4. Conclusions and clinical implications
Oxidative stress and redox regulation play an important role in
peripheral artery disease (PAD). ROS and RNS production largely
depends on the pro-inﬂammatory phenotype of monocytes and myeloid
dendritic cells in patients with PAD [27]. Increased oxidative stress as
well as the pro-inﬂammatory phenotype (as envisaged by higher serum
levels of sTREM) in patients with critical limb ischemia and intermittent
claudication, walking less than 300 m in a treadmill test, are obviously
the primary causes of endothelial dysfunction, which will further
contribute to progression of atherosclerosis (Fig. 5) [26]. Endothelial
dysfunction is an independent risk factor for mortality in claudicants
[132].
Home-based exercise training for a mean time of 12 months reduced
expression of several inﬂammatory surface molecules on monocytes,
dendritic cells and neutrophils in PAD patients as well as serological
markers of inﬂammation, paralleled by an increased pain-free and
absolute walking distance and reduced oxidative burst in whole blood
[25]. In a follow-up study we elucidated that supervised exercise
training was more eﬃcient in improving the inﬂammatory status of
PAD patients and their walking distance than non-supervised exercise
training, although any form of physical activity had beneﬁcial eﬀects
[24]. Further studies on the role of inﬂammation and oxidative stress in
PAD in particular, as well as in other atherosclerotic diseases in general,
are necessary. From a therapeutic point of view, special emphasis
should be laid on the non-pharmacological intervention in form of
(home-based) exercise training [133], which turned out to provide
highly beneﬁcial eﬀects on the quality of life of PAD patients and the
progression of the disease and should be applied besides other
established cardiovascular pharmacological therapies (e.g. anti-athero-
sclerotic, antihypertensive and anti-inﬂammatory drugs like statins,
angiotensin converting enzyme inhibitors and AT1-receptor blockers
[134,135] or cilostazol [118,136,137], also conferring indirect anti-
oxidant eﬀects [138]). A reasonable treatment regimen for PAD is
shown in Fig. 6.
Exercise training in general is highly beneﬁcial for the prognosis in
most cardiovascular diseases, including PAD, by decreasing oxidative
stress and inﬂammation (for review see [139]). However, the prog-
nostic value of supervised exercise training or direct anti-inﬂammatory
and antioxidant therapy (e.g. by monoclonal antibodies against che-
mokines or modern antioxidant strategies like NADPH oxidase inhibi-
tors or Nrf2 activators) on cardiovascular mortality of PAD patients
remains to be established by future clinical studies. A combined
antioxidant, anti-atherosclerotic and anti-inﬂammatory therapy to
target the multifactorial pathology of PAD was suggested in a recent
review article [118] and epidemiological human studies showed that
PAD patients with higher physical activity during daily life have
reduced mortality and cardiovascular events compared with PAD
patients with the lowest physical activity [140].
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